52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Endo Expects To Launch Cellulite Treatment In Q4 2020, If Approved
Endo Reports Q4 Loss Per Share Of $0.92 From Continuing Operations
Endo Names Blaise Coleman President And Chief Executive Officer
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.
Minerva House, Simmonscourt Road
Paul V. Campanelli
Chairman of the Board, President, Chief Executive Officer
Chief Financial Officer, Executive Vice President
Terrance John Coughlin
Chief Operating Officer, Executive Vice President
Executive Vice President and Chief Commercial Officer
Executive Vice President, Chief Commercial Officer - Sterile and Generics
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Drugmaker Endo International Plc <ENDP.O> on Wednesday posted a fourth-quarter profit that beat analysts' estimates, getting a boost from higher sales in its sterile injectables unit.
* ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
Drugmaker Endo International Plc on Wednesday reported a smaller quarterly loss, due to a decrease in asset impairment charges.
* ENDO APPOINTS MARK G. BARBERIO TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
* ENDO INTERNATIONAL PLC - BLAISE COLEMAN IS ENTITLED TO AN ANNUAL BASE SALARY OF $850,000 Source: (https://bit.ly/3bSeFaI) Further company coverage:
* ENDO NAMES BLAISE COLEMAN PRESIDENT AND CHIEF EXECUTIVE OFFICER
Endo International Plc <ENDP.O> beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.
Endo International Plc beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.
Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.
Endo International Plc on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.
Endo International Plc said on Friday the U.S. health regulator has decided https://bit.ly/2XGrm1k not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version...
* PAULSON & CO INC CUTS SHARE STAKE IN VISTRA ENERGY CORP TO 3.7 MILLION SHARES FROM 10 MILLION SHARES - SEC FILING
* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL
A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.
As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.
The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company's shares down as much as 13 percent.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.